

Invoice Number: 0064226-IN

Invoice Date: 4/13/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Accounting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O.	Terms	Salesperson:	Ship VIA *Insure shipment*	Customer Number:
15BNAS20PVB610270	No Terms	JZ	GROUND	0DC0524

NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	48.00	0.00	48.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	20.00	20.00	0.00
Lot Number: 2010455 - PRN P/O AI316	Expiration date: 3/31/2023	Lot Qty: 18.00	
Lot Number: 2010457 - PRN P/O AI316	Expiration date: 3/31/2023	Lot Qty: 2.00	

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRXN)



Invoice Number: 0064277-IN

Invoice Date: 4/15/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Acting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O. 15BNAS20PVB610270	Terms No Terms	Salesperson: JZ	Ship VIA GROUND	Customer Number: ODC0524
------------------------------------	-------------------	--------------------	--------------------	-----------------------------


NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine 200mg 100ct	45.00	0.00	45.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	3.00	3.00	0.00
Lot Number: 2010455 - PRN P/O AI316	Expiration date: 3/31/2023	Lot Qty: 1.00	
Lot Number: 2010457 - PRN P/O AI316	Expiration date: 3/31/2023	Lot Qty: 2.00	

3 bottles
4-20-20

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRXN)



Invoice Number: 0064301-IN

Invoice Date: 4/16/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Accounting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O.	Terms	Salesperson:	Ship VIA *Insure shipment*	Customer Number:
15BNAS20PVB610270	No Terms	JZ	GROUND	0DC0524

NDC#	Ordered	Shipped	Back Ordered
------	---------	---------	--------------

16714-0753-01	32.00	32.00	0.00
---------------	-------	-------	------


Hydroxychloroquine 200mg 100ct

Lot Number:	KD5690 - PRN P/O AI392	Expiration date:	10/31/2022	Lot Qty:	17.00
Lot Number:	KD5692 - PRN P/O AI392	Expiration date:	10/31/2022	Lot Qty:	1.00
Lot Number:	KD8161 - PRN P/O AI392	Expiration date:	10/31/2022	Lot Qty:	2.00
Lot Number:	KD8162 - PRN P/O AI392	Expiration date:	10/31/2022	Lot Qty:	1.00
Lot Number:	KE8014 - PRN P/O AI392	Expiration date:	10/31/2022	Lot Qty:	11.00

00378-0373-01	13.00	13.00	0.00
---------------	-------	-------	------

Hydroxychloroquine 200mg 100/C


Lot Number:	2010455 - PRN P/O AI392	Expiration date:	3/31/2023	Lot Qty:	5.00
Lot Number:	2010457 - PRN P/O AI392	Expiration date:	3/31/2023	Lot Qty:	8.00



Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRNX)



Invoice Number: 0064030-IN

Invoice Date: 4/3/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Accounting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O. 15BNAS20PVB610270	Terms No Terms	Salesperson: JZ	Ship VIA GROUND	Customer Number: 0DC0524
NDC#	Ordered		Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	79.00		0.00	79.00
66993-0057-02 HYDROXYCH SUL TB 200MG PRA100	15.00		5.00	10.00
Lot Number: ET02874 - PRN P/O AI202	Expiration date: 5/31/2022	Lot Qty: 2.00		
Lot Number: ET02874 - PRN P/O AI213	Expiration date: 5/31/2022	Lot Qty: 1.00		
Lot Number: ET02874 - PRN P/O AI246	Expiration date: 5/31/2022	Lot Qty: 2.00		
00591-3041-05 HYDROXYCHLOROQUINE SULF 200MG	5.00		0.00	5.00
68382-0096-05 HYDROXYCH TAB 200MG ZYD 500	2.00		0.00	2.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	45.00		0.00	45.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	2.00		0.00	2.00

5 bottles
4/4

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRXN)



Invoice Number: 0064163-IN

Invoice Date: 4/9/2020

Order Number: 0050556

Order Date 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Accting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O.	Terms	Salesperson:	Ship VIA	Customer Number:
15BNAS20PVB610270	No Terms	JZ	GROUND	ODC0524

NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	42.00	0.00	42.00
66993-0057-02 HYDROXYCH SUL TB 200MG PRA100	10.00	0.00	10.00
00591-3041-05 HYDROXYCHLOROQUINE SULF 200MG	5.00	0.00	5.00
68382-0096-05 HYDROXYCH TAB 200MG ZYD 500	2.00	0.00	2.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	6.00	0.00	6.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	2.00	0.00	2.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	6.00	6.00	0.00

Lot Number: JP7172 - PRN P/O AI328

Expiration date: 10/31/2021

Lot Qty: 6.00

6 bottles 4/14/20

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRNX)

	Date:	Category:	Size:	Quantity:	Disposition:	Vendor or Recipient:
23	4/10/2020	Hydroxychloroquine Tabets (PRN/Other)		6,300	Received From	PRN Pharmaceuticals
27	4/13/2020	Hydroxychloroquine (PRN/Other)		3,100	Received From	PRN Pharmaceuticals
30	4/14/2020	Hydroxychloroquine (PRN/Other)		600	Received From	PRN Pharmaceuticals
31	4/14/2020	Hydroxychloroquine (PRN/Other)		3,200	Received From	PRN Pharmaceuticals
32	4/16/2020	Hydroxychloroquine (PRN/Other)		2,000	Received From	PRN Pharmaceuticals
34	4/20/2020	Hydroxychloroquine (PRN/Other)		300	Received From	PRN Pharmaceuticals
36	4/20/2020	Hydroxychloroquine (PRN/Other)		4,500	Received From	PRN Pharmaceuticals

LOG OF HCQ (non -COVID)TRANSACTIONS FROM CFAD

	Transaction	Balance
1	Received 19 bottles on 4/3/20	19 (1,900)
2	Received 5 bottles on 4/6/20	5 (500)
3	Shipped 2 bottles Elkton 4/7/20	22
4	Brought 2 bottles Oakdale 4/8/20	20
5	Shipped 2 bottles TDG 4/9/20	18
6	Shipped 3 bottles Waseca 4/9/20	15
7	Received 39 bottles on 4/9/20	54
8	Shipped 4 bottles to Tuscon 4/10/20	50
9	Shipped 3 bottles to Forrest City 4/13/20	47
10	Received 31 bottles on 4/13/20	78
11	Shipped 2 bottles to Englewood 4/14/20	76
12	Shipped 3 bottles to OKC 4/14/20	73
13	Received 6 bottles on 4/14/20	79
14	Shipped 2 bottles to Bryan 4/14/20	77
15	Shipped 2 bottles to Devens 4/14/20	75
16	Shipped 2 bottles to Victorville 4/14/20	73
17	Received 32 bottles 4/14/20	105
18	Shipped 2 bottles to Seagoville 4/16/20	103
19	Shipped 1 bottle to Morgantown 4/16/20	102
20	Received 20 bottles on 4/16/20	122
21	Shipped 5 bottles to Carswell 4/16/20	117
22	Received 3 bottles on 4/20/20	120
23	Shipped 2 bottles on Los Angelas 4/20/20	118
24	Received 45 bottles on 4/21/20	163
25	Shipped 2 bottles to Bryan 4/22/20	161
26	Shipped 3 bottles Dublin 4/23/20	158
27	hipped 27 bottles to Carswell 5/11/20	131
28	Shipped 2 bottles to SEA 5/20/20	129
29	Shipped 2 bottles to PHX on 5/26/20	127
30	Shipped 3 bottles to ALD on 5/27/20	124
31	Shipped 3 bottles to FOX on 5/28/2020	121
32	Shipped 5 bottles to SPG 6/9/20	116
33	Shipped 4 bottles to ALI 6/10/20	112
34	Shipped 6 bottles to LEX 6/12/20	106
35		
36		

Inmate	Facility Name	Total Days patient received medication (approx.)	Patient Age	Patient Sex	Filled from SNS?*	Region	Related Serious Adverse Events	Disposition	Reported to FDA?	Comments
(b)(6); (b)(7)(C)	MCC Chicago	1	29	Male	Y	NCR	None	Discharged	Y	Morbidly obese, BMI 45
	MCC Chicago	1	62	Male	Y	NCR	None	Discharged	Y	
	FCI Elkton	4	39	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
										OSA, Obesity (BMI 51.3)
	FCI Elkton	2	61	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Elkton	10	55	Male	Y	NER	None	Discharged	Y	
										Obesity
	FCI Elkton	4	49	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP Obesity
	FCI Terminal Island	4	60	Male	N	WXR	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Elkton	3	64	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Fort Dix	1	57	Male	Y	NER	None	Discharged	Y	
					Y	NER			N/A	None give at FCI Fort Dix, therapy completed prior to return to facility
	FCI Elkton	3	74	Male	Y	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Elkton	10	57	Male	Y	NER	None	Discharged	Y	
	USP Lompoc	2	70	Male	Y	WXR	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	USP Lompoc	2	64	Male	Y	WXR	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	MCC New York	4	64	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
(b)(6); (b)(7)(C)	FCI Elkton	5	44	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Elkton	5	38	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Cumberland	5	83	Male	N	MXR	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Elkton	10	52	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	USP Lompoc	4	49	Male	Y	WXR	None	Discharged	Y	Peripheral Vascular Disease, partial foot amputation
	FCI Elkton	5	59	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCC Oakdale	5	38	Male	N	SCR	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP
	FCI Elkton	3	30	Male	N	NER	None	Discharged	Y	Patient was initiated on treatment while hospitalized in the local community and completed treatment upon return to the Federal prison system. This submission corresponds to the completion of treatment within the FBOP

* Pharmacy filled with "Hydroxychloroquine (COVID-19)" stock

Underlying Conditions

Asthma
Other Chronic Lung Disease
Diabetes
Hypertension
Cardiovascular Disease
Chronic Renal Disease
Chronic Liver Disease
Immunocompromised Condition
Neurologic/Neurodevelopmental/Intellectual Disability
Pregnancy
Smoker
Unknown
Other (specify in comments)

Related Serious Adverse Events

Ventricular arrhythmia
Other cardiac adverse event
Severe hypoglycemia
Hematological effect
Seizures
Unknown
None
Other (specify in comments)

**Estimation of severity of illness
immediately prior to treatment**

Mild
Moderate (eg pneumonia w/o need for supplemental O2)
Severe (e.g. needs supplemental O2)
Critical (e.g. mechanical ventilation)

Disposition

Discharged
Deceased

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT		1. CONTRACT ID CODE 15BNAS20PVB610270	
2. AMENDMENT/MODIFICATION NUMBER P00001	3. EFFECTIVE DATE 04/02/2020	4. REQUISITION/PURCHASE REQUISITION NUMBER	5. PROJECT NUMBER (If applicable)
6. ISSUED BY FEDERAL BUREAU OF PRISONS ACQUISITIONS BRANCH/NATIONAL ACQUISITIONS SECTION 320 FIRST STREET NW ROOM 901-5 WASHINGTON, DC 20534	CODE 15BNAS	7. ADMINISTERED BY (If other than Item 6) CODE	
8. NAME AND ADDRESS OF CONTRACTOR (Number, street, country, state and ZIP Code) PREMIUM RX NATIONAL LLC 15809 CRABBS BRANCH WAY DERWOOD, MD 20855-2635 DUNS: 832402825		(X)	9A. AMENDMENT OF SOLICITATION NUMBER
			9B. DATED (SEE ITEM 11)
			10A. MODIFICATION OF CONTRACT/ORDER NUMBER 15BNAS20PVB610270
		X	10B. DATED (SEE ITEM 13) 03/31/2020
CODE 300576084		FACILITY CODE 832402825	

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

☐ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers ☐ is extended, ☐ is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

SA-2020-02-FP090022UB-97F-3111-2020

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.**IT MODIFIES THE CONTRACT/ORDER NUMBER AS DESCRIBED IN ITEM 14.**

CHECK ONE	A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NUMBER IN ITEM 10A.
X	B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
	D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor ☒ is not, ☐ is required to sign this document and return copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Modify to correct ACCOUNT CLASS from FP070022UB to FP090022UB.

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)		16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Brooke Garcia	
15B. CONTRACTOR/OFFEROR (Signature of person authorized to sign)	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA BROOKE GARCIA (Signature of) Date: 20200402 13:58:14 -0400	16C. DATE SIGNED 04/02/2020

Previous edition unusable

Table of Contents

<u>Section</u>	<u>Description</u>	<u>Page Number</u>
1	Solicitation/Contract Form.....	1
2	Commodity or Services Schedule.....	3
3	Contract Clauses.....	3
4	List of Attachments.....	3

Section 2 - Commodity or Services Schedule

Protective Gowns

SCHEDULE OF SUPPLIES/SERVICES

CONTINUATION SHEET

ITEM NO.	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	FEEs	AMOUNT
					PREVIOUS TOTAL	\$60,000.00
					CHANGE	\$0.00
					CURRENT TOTAL	\$60,000.00

FUNDING DETAILS:

ITEM NO.	FUNDING LINE	OBLIGATED AMOUNT	ACCOUNTING CODES
N/A	1	Previous: \$60,000.00 Change: \$0.00 Current: \$60,000.00	SA-2020-02-FP090022UB-97F-3111-2020
		PREVIOUS: \$60,000.00 CHANGE: \$0.00 CURRENT: \$60,000.00	

Section 3 - Contract Clauses

No Clauses

Section 4 - List of Attachments

No Clauses

Identifier	Title	Number of Pages
1	print BPO/15BNAS20PVB610270 2020-04-02 16:46:24.473 1128944065 - DELETED	

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL ITEMS OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24 & 30				1. REQUISITION NUMBER	
2. CONTRACT NO. 15BNAS20PVB610270		3. AWARD/EFFECTIVE DATE 03/31/2020		4. ORDER NUMBER	
5. SOLICITATION NUMBER		6. SOLICITATION ISSUE DATE		7. FOR SOLICITATION INFORMATION CALL:	
a. NAME (b)(6); (b)(7)(C)		b. TELEPHONE NUMBER (No collect calls)		8. OFFER DUE DATE / LOCAL TIME	
9. ISSUED BY Federal Bureau of Prisons Acquisitions Branch/National Acquisitions Section 320 First Street NW Room 901-5 WASHINGTON, DC 20534		CODE 15BNAS		10. THE ACQUISITION IS <input type="checkbox"/> UNRESTRICTED OR <input checked="" type="checkbox"/> SET ASIDE: 100.00 % FOR	
<input checked="" type="checkbox"/> SMALL BUSINESS		<input type="checkbox"/> WOMEN-OWNED SMALL BUSINESS (WOSB) ELIGIBLE UNDER THE WOMEN-OWNED SMALL BUSINESS PROGRAM		NAICS: 423450	
<input type="checkbox"/> HUBZONE SMALL BUSINESS		<input type="checkbox"/> EDWOSB		SIZE STANDARD: 500 Employees	
<input type="checkbox"/> SERVICE-DISABLED VETERAN-OWNED SMALL BUSINESS		<input type="checkbox"/> 8(A)			
11. DELIVERY FOR FOB DESTINATION UNLESS BLOCK IS MARKED <input type="checkbox"/> SEE SCHEDULE		12. DISCOUNT TERMS NET 30		13. RATING	
15. DELIVER TO Federal Bureau of Prisons (b)(7)(E); (b)(7)(F)		CODE		14. METHOD OF SOLICITATION <input checked="" type="checkbox"/> RFQ <input type="checkbox"/> IFB <input type="checkbox"/> RFP	
16. ADMINISTERED BY Federal Bureau of Prisons Acquisitions Branch/National Acquisitions Section 320 First Street NW Room 901-5 WASHINGTON, DC 20534		CODE BNAS			
17a. CONTRACTOR/OFFEROR PREMIUM RX NATIONAL LLC 15809 CRABBS BRANCH WAY DERWOOD, MD 20855-2635 DUNS: 832402825 TELEPHONE NO.		CODE 300576084		FACILITY CODE 832402825	
18a. PAYMENT WILL BE MADE BY Federal Bureau of Prisons Acquisitions Branch/Central Office Business Office 320 First Street NW Suite 5006 WASHINGTON, DC 20534		CODE 15B700		Please ensure invoice ref the full contract/order number cobusinessoffice@bop.gov	
<input type="checkbox"/> 17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER		18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED <input type="checkbox"/> SEE ADDENDUM			
19. ITEM NO.	20. SCHEDULE OF SUPPLIES/SERVICES	21. QUANTITY	22. UNIT	23. UNIT PRICE	24. AMOUNT
	Delivery Date: 04/06/2020 Hydroxychloroquine Sulfate Tab 200 MG YREGDOC#: VB610270 Small Business See Continuation Sheet(s) <i>(Use Reverse and/or Attach Additional Sheets as Necessary)</i>				
25. ACCOUNTING AND APPROPRIATION DATA SA-2020-02-FP070022UB-97F-3111-2020				26. TOTAL AWARD AMOUNT (For Govt. Use Only) \$60,000.00	
<input type="checkbox"/> 27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4, FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA				<input type="checkbox"/> ARE <input type="checkbox"/> ARE NOT ATTACHED	
<input checked="" type="checkbox"/> 27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4, FAR 52.212-5 IS ATTACHED. ADDENDA				<input type="checkbox"/> ARE <input checked="" type="checkbox"/> ARE NOT ATTACHED	
<input type="checkbox"/> 28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _____ COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED				<input checked="" type="checkbox"/> 29. AWARD OF CONTRACT: REF. _____ OFFER DATED 03/31/2020 . YOUR OFFER ON SOLICITATION (BLOCK 5) INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE SET FORTH HEREIN, IS ACCEPTED AS TO ITEMS:	
30a. SIGNATURE OF OFFEROR/CONTRACTOR		31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER) BROOKE GARCIA (b)(7)(E); (b)(7)(F) <small>Date: 2020.03.31 10:09:12 -0400</small>			
30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT)		30c. DATE SIGNED		31b. NAME OF THE CONTRACTING OFFICER (TYPE OR PRINT)	
				Brooke Garcia	
				03/31/2020	

19. ITEM NO.	20. SCHEDULE OF SUPPLIES/SERVICES	21. QUANTITY	22. UNIT	23. UNIT PRICE	24. AMOUNT

32a. QUANTITY IN COLUMN 21 HAS BEEN

☐ RECEIVED ☐ INSPECTED ☐ ACCEPTED, AND CONFORMS TO THE CONTRACT, EXCEPT AS NOTED: _____

32b. SIGNATURE OF AUTHORIZED GOVERNMENT REPRESENTATIVE

32c. DATE

32d. PRINTED NAME AND TITLE OF AUTHORIZED GOVERNMENT REPRESENTATIVE

32e. MAILING ADDRESS OF AUTHORIZED GOVERNMENT REPRESENTATIVE

32f. TELEPHONE NUMBER OF AUTHORIZED GOVERNMENT REPRESENTATIVE

32g. E-MAIL OF AUTHORIZED GOVERNMENT REPRESENTATIVE

33. SHIP NUMBER

34. VOUCHER NUMBER

35. AMOUNT VERIFIED
CORRECT FOR

36. PAYMENT

☐ COMPLETE ☐ PARTIAL ☐ FINAL

37. CHECK NUMBER

38. S/R ACCOUNT NUMBER

39. S/R VOUCHER NUMBER

40. PAID BY

41a. I CERTIFY THIS ACCOUNT IS CORRECT AND PROPER FOR PAYMENT

42a. RECEIVED BY (*Print*)

41b. SIGNATURE AND TITLE OF CERTIFYING OFFICER

41c. DATE

42b. RECEIVED AT (*Location*)42c. DATE REC'D (*YY/MM/DD*)

42d. TOTAL CONTAINERS

Table of Contents

<u>Section</u>	<u>Description</u>	<u>Page Number</u>
1	Solicitation/Contract Form.....	1
2	Commodity or Services Schedule.....	4
3	Contract Clauses.....	5
	52.212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders--	
	Commercial Items (Jan 2020).....	
4	List of Attachments.....	12

Section 2 - Commodity or Services Schedule

SCHEDULE OF SUPPLIES/SERVICES

CONTINUATION SHEET

ITEM NO.	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	FEES	AMOUNT
0001	Firm Fixed Price Hydroxychloroquine Sulfate Tab 200 MG PSC: 6515	200.000000	EA	\$300.0000	\$0.00	\$60,000.00
					TOTAL	\$60,000.00

FUNDING DETAILS:

ITEM NO.	FUNDING LINE	OBLIGATED AMOUNT	ACCOUNTING CODES
N/A	1	\$60,000.00	SA-2020-02-FP070022UB-97F-3111-2020
		TOTAL: \$60,000.00	

Section 3 - Contract Clauses

A.1 ADDENDUM TO FAR 52.212-4, Contract Terms and Conditions-Commercial Items (Oct 2018)

The terms and conditions for the following clauses are hereby incorporated into this solicitation and resulting contract as an addendum to FAR clause 52.212-4.

Clauses By Reference

52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)

This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es): www.acquisition.gov

Clause	Title	Fill-ins (if applicable)
52.212-4	Contract Terms and Conditions-Commercial Items (Oct 2018)	

Clauses By Full Text

[END OF ADDENDUM TO FAR 52.212-4]

52.212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders--Commercial Items (Jan 2020)

(a) The Contractor shall comply with the following Federal Acquisition Regulation (FAR) clauses, which are incorporated in this contract by reference, to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

- (1) 52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (Jan 2017) (section 743 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)).
- (2) 52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (Jul 2018) (Section 1634 of Pub. L. 115-91).
- (3) 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (Aug 2019) (Section 889(a)(1)(A) of Pub. L. 115-232).
- (4) 52.209-10, Prohibition on Contracting with Inverted Domestic Corporations (Nov 2015).
- (5) 52.233-3, Protest After Award (Aug 1996) (31 U.S.C. 3553).
- (6) 52.233-4, Applicable Law for Breach of Contract Claim (Oct 2004)(Public Laws 108-77 and 108-78 (19 U.S.C. 3805 note)).

(b) The Contractor shall comply with the FAR clauses in this paragraph (b) that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

[Contracting Officer check as appropriate.]

X (1) 52.203-6, Restrictions on Subcontractor Sales to the Government (Sept 2006), with Alternate I (Oct 1995) (41 U.S.C. 4704 and 10 U.S.C. 2402).

X (2) 52.203-13, Contractor Code of Business Ethics and Conduct (Oct 2015) (41 U.S.C. 3509)).

__ (3) 52.203-15, Whistleblower Protections under the American Recovery and Reinvestment Act of 2009 (June 2010) (Section 1553 of Pub. L. 111-5). (Applies to contracts funded by the American Recovery and Reinvestment Act of 2009.)

__ (4) 52.204-10, Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2018) (Pub. L. 109-282) (31 U.S.C. 6101 note).

__ (5) [Reserved].

__ (6) 52.204-14, Service Contract Reporting Requirements (Oct 2016) (Pub. L. 111-117, section 743 of Div. C).

__ (7) 52.204-15, Service Contract Reporting Requirements for Indefinite-Delivery Contracts (Oct 2016) (Pub. L. 111-117, section 743 of Div. C).

__ (8) 52.209-6, Protecting the Government's Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment. (Oct 2015) (31 U.S.C. 6101 note).

__ (9) 52.209-9, Updates of Publicly Available Information Regarding Responsibility Matters (Oct 2018) (41 U.S.C. 2313).

__ (10) [Reserved].

__ (11)(i) 52.219-3, Notice of HUBZone Set-Aside or Sole-Source Award (Nov 2011) (15 U.S.C. 657a).

__ (ii) Alternate I (Nov 2011) of 52.219-3.

__ (12)(i) 52.219-4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns (Oct 2014) (if the offeror elects to waive the preference, it shall so indicate in its offer) (15 U.S.C. 657a).

__ (ii) Alternate I (Jan 2011) of 52.219-4.

__ (13) [Reserved]

X (14)(i) 52.219-6, Notice of Total Small Business Set-Aside (Nov 2011) (15 U.S.C. 644).

__ (ii) Alternate I (Nov 2011).

__ (iii) Alternate II (Nov 2011).

__ (15)(i) 52.219-7, Notice of Partial Small Business Set-Aside (June 2003) (15 U.S.C. 644).

__ (ii) Alternate I (Oct 1995) of 52.219-7.

__ (iii) Alternate II (Mar 2004) of 52.219-7.

X (16) 52.219-8, Utilization of Small Business Concerns (Oct 2018) (15 U.S.C. 637(d)(2) and (3)).

__ (17)(i) 52.219-9, Small Business Subcontracting Plan (Aug 2018) (15 U.S.C. 637(d)(4)).

__ (ii) Alternate I (Nov 2016) of 52.219-9.

__ (iii) Alternate II (Nov 2016) of 52.219-9.

__ (iv) Alternate III (Nov 2016) of 52.219-9.

__ (v) Alternate IV (Aug 2018) of 52.219-9.

X (18) 52.219-13, Notice of Set-Aside of Orders (Nov 2011) (15 U.S.C. 644(r)).

X (19) 52.219-14, Limitations on Subcontracting (Jan 2017) (15 U.S.C. 637(a)(14)).

__ (20) 52.219-16, Liquidated Damages--Subcon-tracting Plan (Jan 1999) (15 U.S.C. 637(d)(4)(F)(i)).

__ (21) 52.219-27, Notice of Service-Disabled Veteran-Owned Small Business Set-Aside (Oct 2019) (15 U.S.C. 657f).

__ (22) 52.219-28, Post Award Small Business Program Rerepresentation (Jul 2013) (15 U.S.C. 632(a)(2)).

__ (23) 52.219-29, Notice of Set-Aside for, or Sole Source Award to, Economically Disadvantaged Women-Owned Small Business Concerns (Dec 2015) (15 U.S.C. 637(m)).

__ (24) 52.219-30, Notice of Set-Aside for, or Sole Source Award to, Women-Owned Small Business Concerns Eligible Under the Women-Owned Small Business Program (Dec 2015) (15 U.S.C. 637(m)).

X (25) 52.222-3, Convict Labor (June 2003) (E.O. 11755).

X (26) 52.222-19, Child Labor--Cooperation with Authorities and Remedies (Jan 2020) (E.O. 13126).

X (27) 52.222-21, Prohibition of Segregated Facilities (Apr 2015).

X (28)(i) 52.222-26, Equal Opportunity (Sept 2016) (E.O. 11246).

__ (ii) Alternate I (Feb 1999) of 52.222-26.

__ (29)(i) 52.222-35, Equal Opportunity for Veterans (Oct 2015)(38 U.S.C. 4212).

__ (ii) Alternate I (July 2014) of 52.222-35.

__ (30)(i) 52.222-36, Equal Opportunity for Workers with Disabilities (July 2014) (29 U.S.C. 793).

__ (ii) Alternate I (July 2014) of 52.222-36.

__ (31) 52.222-37, Employment Reports on Veterans (Feb 2016) (38 U.S.C. 4212).

__ (32) 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec 2010) (E.O. 13496).

X (33)(i) 52.222-50, Combating Trafficking in Persons (Jan 2019) (22 U.S.C. chapter 78 and E.O. 13627).

__ (ii) Alternate I (Mar 2015) of 52.222-50 (22 U.S.C. chapter 78 and E.O. 13627).

__ (34) 52.222-54, Employment Eligibility Verification (Oct 2015). (Executive Order 12989). (Not applicable to the acquisition of commercially available off-the-shelf items or certain other types of commercial items as prescribed in 22.1803.)

__ (35)(i) 52.223-9, Estimate of Percentage of Recovered Material Content for EPA-Designated Items (May 2008) (42 U.S.C. 6962(c) (3)(A)(ii)). (Not applicable to the acquisition of commercially available off-the-shelf items.)

__ (ii) Alternate I (May 2008) of 52.223-9 (42 U.S.C. 6962(i)(2)(C)). (Not applicable to the acquisition of commercially available off-the-shelf items.)

__ (36) 52.223-11, Ozone-Depleting Substances and High Global Warming Potential Hydrofluorocarbons (Jun 2016) (E.O. 13693).

__ (37) 52.223-12, Maintenance, Service, Repair, or Disposal of Refrigeration Equipment and Air Conditioners (Jun 2016) (E.O. 13693).

__ (38)(i) 52.223-13, Acquisition of EPEAT®-Registered Imaging Equipment (Jun 2014) (E.O.s 13423 and 13514).

__ (ii) Alternate I (Oct 2015) of 52.223-13.

___ (39)(i) 52.223-14, Acquisition of EPEAT®-Registered Televisions (Jun 2014) (E.O.s 13423 and 13514).

___ (ii) Alternate I (Jun 2014) of 52.223-14.

___ (40) 52.223-15, Energy Efficiency in Energy-Consuming Products (Dec 2007) (42 U.S.C. 8259b).

___ (41)(i) 52.223-16, Acquisition of EPEAT®-Registered Personal Computer Products (Oct 2015) (E.O.s 13423 and 13514).

___ (ii) Alternate I (Jun 2014) of 52.223-16.

___ (42) 52.223-18, Encouraging Contractor Policies to Ban Text Messaging While Driving (Aug 2011) (E.O. 13513).

___ (43) 52.223-20, Aerosols (Jun 2016) (E.O. 13693).

___ (44) 52.223-21, Foams (Jun 2016) (E.O. 13693).

___ (45)(i) 52.224-3, Privacy Training (Jan 2017) (5 U.S.C. 552a).

___ (ii) Alternate I (Jan 2017) of 52.224-3.

X (46) 52.225-1, Buy American--Supplies (May 2014) (41 U.S.C. chapter 83).

X (47)(i) 52.225-3, Buy American--Free Trade Agreements--Israeli Trade Act (May 2014) (41 U.S.C. chapter 83, 19 U.S.C. 3301 note, 19 U.S.C. 2112 note, 19 U.S.C. 3805 note, 19 U.S.C. 4001 note, Pub. L. 103-182, 108-77, 108-78, 108-286, 108-302, 109-53, 109-169, 109-283, 110-138, 112-41, 112-42, and 112-43).

___ (ii) Alternate I (May 2014) of 52.225-3.

___ (iii) Alternate II (May 2014) of 52.225-3.

___ (iv) Alternate III (May 2014) of 52.225-3.

___ (48) 52.225-5, Trade Agreements (Oct 2019) (19 U.S.C. 2501, et seq., 19 U.S.C. 3301 note).

X (49) 52.225-13, Restrictions on Certain Foreign Purchases (June 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury).

___ (50) 52.225-26, Contractors Performing Private Security Functions Outside the United States (Oct 2016) (Section 862, as amended, of the National Defense Authorization Act for Fiscal Year 2008; 10 U.S.C. 2302 Note).

___ (51) 52.226-4, Notice of Disaster or Emergency Area Set-Aside (Nov 2007) (42 U.S.C. 5150).

___ (52) 52.226-5, Restrictions on Subcontracting Outside Disaster or Emergency Area (Nov 2007) (42 U.S.C. 5150).

___ (53) 52.232-29, Terms for Financing of Purchases of Commercial Items (Feb 2002) (41 U.S.C. 4505, 10 U.S.C. 2307(f)).

___ (54) 52.232-30, Installment Payments for Commercial Items (Jan 2017) (41 U.S.C. 4505, 10 U.S.C. 2307(f)).

X (55) 52.232-33, Payment by Electronic Funds Transfer--System for Award Management (Oct 2018) (31 U.S.C. 3332).

___ (56) 52.232-34, Payment by Electronic Funds Transfer--Other than System for Award Management (Jul 2013) (31 U.S.C. 3332).

___ (57) 52.232-36, Payment by Third Party (May 2014) (31 U.S.C. 3332).

___ (58) 52.239-1, Privacy or Security Safeguards (Aug 1996) (5 U.S.C. 552a).

___ (59) 52.242-5, Payments to Small Business Subcontractors (Jan 2017)(15 U.S.C. 637(d)(13)).

__ (60)(i) 52.247-64, Preference for Privately Owned U.S.-Flag Commercial Vessels (Feb 2006) (46 U.S.C. Appx. 1241(b) and 10 U.S.C. 2631).

__ (ii) Alternate I (Apr 2003) of 52.247-64.

__ (iii) Alternate II (Feb 2006) of 52.247-64.

(c) The Contractor shall comply with the FAR clauses in this paragraph (c), applicable to commercial services, that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

[Contracting Officer check as appropriate.]

__ (1) 52.222-17, Nondisplacement of Qualified Workers (May 2014)(E.O. 13495).

__ (2) 52.222-41, Service Contract Labor Standards (Aug 2018) (41 U.S.C. chapter 67).

__ (3) 52.222-42, Statement of Equivalent Rates for Federal Hires (May 2014) (29 U.S.C. 206 and 41 U.S.C. chapter 67).

__ (4) 52.222-43, Fair Labor Standards Act and Service Contract Labor Standards-Price Adjustment (Multiple Year and Option Contracts) (Aug 2018) (29 U.S.C. 206 and 41 U.S.C. chapter 67).

__ (5) 52.222-44, Fair Labor Standards Act and Service Contract Labor Standards--Price Adjustment (May 2014) (29 U.S.C. 206 and 41 U.S.C. chapter 67).

__ (6) 52.222-51, Exemption from Application of the Service Contract Labor Standards to Contracts for Maintenance, Calibration, or Repair of Certain Equipment--Requirements (May 2014) (41 U.S.C. chapter 67).

__ (7) 52.222-53, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services--Requirements (May 2014) (41 U.S.C. chapter 67).

__ (8) 52.222-55, Minimum Wages Under Executive Order 13658 (Dec 2015).

__ (9) 52.222-62, Paid Sick Leave Under Executive Order 13706 (Jan 2017) (E.O. 13706).

__ (10) 52.226-6, Promoting Excess Food Donation to Nonprofit Organizations (May 2014) (42 U.S.C. 1792).

(d) *Comptroller General Examination of Record.* The Contractor shall comply with the provisions of this paragraph (d) if this contract was awarded using other than sealed bid, is in excess of the simplified acquisition threshold, and does not contain the clause at 52.215-2, Audit and Records--Negotiation.

(1) The Comptroller General of the United States, or an authorized representative of the Comptroller General, shall have access to and right to examine any of the Contractor's directly pertinent records involving transactions related to this contract.

(2) The Contractor shall make available at its offices at all reasonable times the records, materials, and other evidence for examination, audit, or reproduction, until 3 years after final payment under this contract or for any shorter period specified in FAR subpart 4.7, Contractor Records Retention, of the other clauses of this contract. If this contract is completely or partially terminated, the records relating to the work terminated shall be made available for 3 years after any resulting final termination settlement. Records relating to appeals under the disputes clause or to litigation or the settlement of claims arising under or relating to this contract shall be made available until such appeals, litigation, or claims are finally resolved.

(3) As used in this clause, records include books, documents, accounting procedures and practices, and other data, regardless of type and regardless of form. This does not require the Contractor to create or maintain any record that the Contractor does not maintain in the ordinary course of business or pursuant to a provision of law.

(e)(1) Notwithstanding the requirements of the clauses in paragraphs (a), (b), (c), and (d) of this clause, the Contractor is not required to flow down any FAR clause, other than those in this paragraph (e)(1) in a subcontract for commercial items. Unless otherwise indicated below, the extent of the flow down shall be as required by the clause--

(i) 52.203-13, Contractor Code of Business Ethics and Conduct (Oct 2015) (41 U.S.C. 3509).

- (ii) 52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (Jan 2017) (section 743 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)).
- (iii) 52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (Jul 2018) (Section 1634 of Pub. L. 115-91).
- (iv) 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (Aug 2019) (Section 889(a)(1)(A) of Pub. L. 115-232).
- (v) 52.219-8, Utilization of Small Business Concerns (Oct 2018) (15 U.S.C. 637(d)(2) and (3)), in all subcontracts that offer further subcontracting opportunities. If the subcontract (except subcontracts to small business concerns) exceeds \$700,000 (\$1.5 million for construction of any public facility), the subcontractor must include 52.219-8 in lower tier subcontracts that offer subcontracting opportunities.
- (vi) 52.222-17, Nondisplacement of Qualified Workers (May 2014) (E.O. 13495). Flow down required in accordance with paragraph (l) of FAR clause 52.222-17.
- (vii) 52.222-21, Prohibition of Segregated Facilities (Apr 2015)
- (viii) 52.222-26, Equal Opportunity (Sept 2016) (E.O. 11246).
- (ix) 52.222-35, Equal Opportunity for Veterans (Oct 2015) (38 U.S.C. 4212).
- (x) 52.222-36, Equal Opportunity for Workers with Disabilities (Jul 2014) (29 U.S.C. 793).
- (xi) 52.222-37, Employment Reports on Veterans (Feb 2016) (38 U.S.C. 4212)
- (xii) 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec 2010) (E.O. 13496). Flow down required in accordance with paragraph (f) of FAR clause 52.222-40.
- (xiii) 52.222-41, Service Contract Labor Standards (Aug 2018) (41 U.S.C. chapter 67).
- (xiv) (A) 52.222-50, Combating Trafficking in Persons (Jan 2019) (22 U.S.C. chapter 78 and E.O 13627).
- (B) Alternate I (Mar 2015) of 52.222-50 (22 U.S.C. chapter 78 and E.O 13627).
- (xv) 52.222-51, Exemption from Application of the Service Contract Labor Standards to Contracts for Maintenance, Calibration, or Repair of Certain Equipment-Requirements (May 2014) (41 U.S.C. chapter 67).
- (xvi) 52.222-53, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services-Requirements (May 2014) (41 U.S.C. chapter 67).
- (xvii) 52.222-54, Employment Eligibility Verification (Oct 2015) (E.O. 12989).
- (xix) 52.222-55, Minimum Wages Under Executive Order 13658 (Dec 2015).
- (xviii) 52.222-62, Paid Sick Leave Under Executive Order 13706 (Jan 2017) (E.O. 13706).
- (xx)(A) 52.224-3, Privacy Training (Jan 2017) (5 U.S.C. 552a).
- (B) Alternate I (Jan 2017) of 52.224-3.
- (xxi) 52.225-26, Contractors Performing Private Security Functions Outside the United States (Oct 2016) (Section 862, as amended, of the National Defense Authorization Act for Fiscal Year 2008; 10 U.S.C. 2302 Note).
- (xxii) 52.226-6, Promoting Excess Food Donation to Nonprofit Organizations (May 2014) (42 U.S.C. 1792). Flow down required in accordance with paragraph (e) of FAR clause 52.226-6.

(xxiii) 52.247-64, Preference for Privately Owned U.S.-Flag Commercial Vessels (Feb 2006) (46 U.S.C. Appx. 1241(b) and 10 U.S.C. 2631). Flow down required in accordance with paragraph (d) of FAR clause 52.247-64.

(2) While not required, the Contractor may include in its subcontracts for commercial items a minimal number of additional clauses necessary to satisfy its contractual obligations.

(End of clause)

Section 4 - List of Attachments

This Section Is Intentionally Left Blank

Institution/Facility Central Office	Requisitioning Department HSD	Date of Order Mar 12, 2020 3/31/2020
Requestor Name/Telephone Number (b)(6); (b)(7)(C)		Receiving Report # (Warehouse Use) Warehouse Signature:

Item No.	GSA/Other Stock No.	DESCRIPTION	QTY	UNIT	UNIT PRICE	AMOUNT
1		Hydroxychloroquine Sulfate Tab 200 MG	200	Bottles	\$300.00	\$60,000.00
		Ship to:				
		Pharmacy				
		(b)(7)(E); (b)(7)(F)				
		Due to the unavailability of a SS initiative, it was Not Utilized.				
		(b)(6); (b)(7)(C)				

Bureau of Prisons Tax ID: #53-0205705					TOTAL AMOUNT		\$60,000.00	
Price Quotes	Item 1	Item 2	Item 3	Item 4	Item 1	Item 2	Item 3	Item 4
Source/Vendor Name	Premium Rx National, LLC			(b)(4); (b)(3); 41 U.S.C. § 423(a)(1)				
Street	15809 Crabbs Branch Way							
City, State, Zip	Derwood MD 20855-2635							
Contact Name/Phone	(b)(6); (b)(7)(C)							

APPR	ACCOUNT CLASS (Accounting Code for purchase cards)	PROJ	SUB OBJECT	Date Required 4/15/2020	Deliver To	Requested By (b)(6); (b)(7)(C)
02	FP RR II 22UB	97F		Approving Official/Cost Center Manager WILLIAM O'REGAN	Date 2020.03.31 07:36:05 -04'00'	Digitally signed by WILLIAM O'REGAN

TO BE COMPLETED BY PROCUREMENT STAFF

Vendor/Address: Premium Rx National 15809 Crabbs Branch Way Derwood, MD 20855	IG N	PO NUMBER 15BNAS20PVB610270	DESG 10270	RECYCLE N	CCR Y
	Payment Terms Net 30		Ship Via C/M		
	FOB (check one) <input type="checkbox"/> Origin <input type="checkbox"/> Destination				
Contact Name/Telephone/Fax	QUOTE SOURCE (check one) <input type="checkbox"/> Telephone <input type="checkbox"/> Catalog <input type="checkbox"/> FSS <input type="checkbox"/> Price List <input type="checkbox"/> Internet <input type="checkbox"/> IFB <input type="checkbox"/> RFP <input type="checkbox"/> RFQ				
TIN	YREGDOC# VB610270		RP#		
SUPPLIES ONLY: Excess and rehabilitated sources have been screened and the property is not available from these sources.	CONTRACTING OFFICER BROOKE GARCIA		Digitally signed by BROOKE GARCIA, a true (b)(7)(E); (b)(7)(F) Date: 2020.03.31 09:41:11 -04'00'		
<input type="checkbox"/> WARNING! AMMUNITION/WEAPONS/HAZARDOUS MATERIAL FOR PENAL INSTITUTION - DELIVER TO ARMORY/SPECIFIED STAFF ONLY	CARDHOLDER (For Purchase Card acquisitions)			DATE	



Invoice Number: 0064004-IN

Invoice Date: 4/2/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Acting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O. 15BNAS20PVB610270	Terms No Terms	Salesperson: JZ	Ship VIA <i>*Insure shipment*</i> 1 DAY PRIORITY	Customer Number: 0DC0524	
NDC#			Ordered	Shipped	Back Ordered
00378-0373-01 Hydroxychloroquine 200mg 100/C			45.00	0.00	45.00
00781-5994-01 Hydroxychloroquine Sulf 200mg			2.00	0.00	2.00

HOLD AND SHIP TOGETHER. WE WILL GRAB WHATEVER COUNT BOTTLES WE SEE TO ADD UP TO 20K TOTAL TABS

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRXN)



Invoice Number: 0064004-IN

Invoice Date: 4/2/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)


Bill To:

Federal Bureau of Prisons
Finance Branch/Accting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O. 15BNAS20PVB610270	Terms No Terms	Salesperson: JZ	Ship VIA <i>*Insure shipment*</i> 1 DAY PRIORITY	Customer Number: 0DC0524
------------------------------------	-------------------	--------------------	---	-----------------------------

NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	79.00	0.00	79.00
66993-0057-02 HYDROXYCH SUL TB 200MG PRA100	15.00	0.00	15.00
00591-3041-05 HYDROXYCHLOROQUINE SULF 200MG	5.00	0.00	5.00
57664-0761-88 HYDROXYCHLOROQUINE SULF 200MG	14.00	14.00	0.00
Lot Number: AVJ0912A - PRN P/O AI116	Expiration date: 6/30/2021	Lot Qty: 3.00	
Lot Number: AVJ0955A - PRN P/O AI116	Expiration date: 7/31/2021	Lot Qty: 10.00	
Lot Number: AVJ0956A - PRN P/O AI116	Expiration date: 7/31/2021	Lot Qty: 1.00	
16714-0753-01 Hydroxychloroquine Sulf Tab 20	5.00	0.00	0.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	5.00	5.00	0.00
Lot Number: JP7172 - PRN P/O AI099	Expiration date: 10/31/2021	Lot Qty: 5.00	
68382-0096-05 HYDROXYCH TAB 200MG ZYD 500	2.00	0.00	2.00

Continued



Invoice Number: 0064050-IN

Invoice Date: 4/6/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Acting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O.	Terms	Salesperson:	Ship VIA *Insure shipment*	Customer Number:
15BNAS20PVB610270	No Terms	JZ	GROUND	0DC0524

NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	79.00	0.00	79.00
66993-0057-02 HYDROXYCH SUL TB 200MG PRA100	10.00	0.00	10.00
00591-3041-05 HYDROXYCHLOROQUINE SULF 200MG	5.00	0.00	5.00
68382-0096-05 HYDROXYCH TAB 200MG ZYD 500	2.00	0.00	2.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	45.00	39.00	6.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	2.00	0.00	2.00

Lot Number: 2010454 - PRN P/O AI222

Expiration date: 3/31/2023


Lot Qty:

39.00

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRXN)



Invoice Number: 0064117-IN

Invoice Date: 4/8/2020

Order Number: 0050556

Order Date 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Accounting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O.	Terms	Salesperson:	Ship VIA *Insure shipment*	Customer Number:
15BNAS20PVB610270	No Terms	JZ	GROUND	0DC0524

NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	52.00	0.00	52.00
66993-0057-02 HYDROXYCH SUL TB 200MG PRA100	10.00	0.00	10.00
00591-3041-05 HYDROXYCHLOROQUINE SULF 200MG	5.00	0.00	5.00
68382-0096-05 HYDROXYCH TAB 200MG ZYD 500	2.00	0.00	2.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	6.00	0.00	6.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	2.00	0.00	2.00
16714-0753-01 Hydroxychloroquine 200mg 100ct	27.00	27.00	0.00

Lot Number: KD5690 - PRN P/O AI307

Expiration date: 10/31/2022

Lot Qty: 27.00

27 received
4/13/20

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRXN)



Invoice Number: 0064117-IN

Invoice Date: 4/8/2020

Order Number: 0050556

Order Date: 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Accting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O.	Terms	Salesperson:	Ship VIA *Insure shipment*	Customer Number:
15BNAS20PVB610270	No Terms	JZ	GROUND	0DC0524

NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	48.00	0.00	48.00
66993-0057-02 HYDROXYCH SUL TB 200MG PRA100	10.00	0.00	10.00
00591-3041-05 HYDROXYCHLOROQUINE SULF 200MG	5.00	0.00	5.00
68382-0096-05 HYDROXYCH TAB 200MG ZYD 500	2.00	0.00	2.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	6.00	0.00	6.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	2.00	0.00	2.00
16714-0753-01 Hydroxychloroquine 200mg 100ct	27.00	27.00	0.00

Lot Number: KD5690 - PRN P/O AI307

Expiration date: 10/31/2022

Lot Qty: 27.00

16714-0753-01
Hydroxychloroquine 200mg 100ct

4.00 4.00

0.00

In this box

Continued

4 Received
4/13/20



Invoice Number: 0064194-IN

Invoice Date: 4/10/2020

Order Number: 0050556

Order Date 3/30/2020

Ship To:

(b)(7)(E); (b)(7)(F)

Bill To:

Federal Bureau of Prisons
Finance Branch/Accounting Oper
320 First St NW
Room 901-4
Washington, DC 20534

Customer P.O.	Terms	Salesperson:	Ship VIA *Insure shipment*	Customer Number:
15BNAS20PVB610270	No Terms	JZ	GROUND	ODC0524

NDC#	Ordered	Shipped	Back Ordered
16714-0753-01 Hydroxychloroquine Sulf Tab 20	10.00	0.00	10.00
66993-0057-02 HYDROXYCH SUL TB 200MG PRA100	10.00	0.00	10.00
00591-3041-05 HYDROXYCHLOROQUINE SULF 200MG	5.00	0.00	5.00
68382-0096-05 HYDROXYCH TAB 200MG ZYD 500	2.00	0.00	2.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	6.00	0.00	6.00
00781-5994-01 Hydroxychloroquine Sulf 200mg	2.00	0.00	2.00
00378-0373-01 Hydroxychloroquine 200mg 100/C	32.00	32.00	0.00

Lot Number: 2010455 - PRN P/O AI316

Expiration date: 3/31/2023

Lot Qty: 32.00

Terms of Sale: All sales final. Product is non-returnable. Claims for damages must be made within 48 hours of receipt. All past due invoices are subject to a 1.5% interest charge per month, totaling 18% annually. Buyer agrees that this invoice serves as a security agreement under the Uniform Commercial Code. If necessary to institute legal action to enforce the collection of the amount due under the invoice, buyer waives all notice or demand and agrees to pay all necessary costs and reasonable attorney fees. Any disputes with regard to payment are subject to the laws of the State of Maryland. In the case of a mandatory recall by the FDA or the manufacturer Premium Rx National will reimburse the cost of the product in exchange for the recalled item.

Premium Rx National, LLC

Remit Payments To:
15809 Crabbs Branch Way
Rockville, MD 20855
(877) 862-7796 (PRXN)

Information Regarding Use of Hydroxychloroquine (HCQ) or Azithromycin (AZ) for the Treatment of COVID-19

There are currently no FDA-approved drugs used specifically for the treatment of COVID-19 infected patients. Studies have shown that azithromycin and hydroxychloroquine have antagonistic effects against COVID-19 *in vitro*. As a result, they have garnered much attention as potential treatments for patients infected with COVID-19. However, the current body of literature does not support the routine use of HCQ for patients with confirmed COVID-19. There have been no randomized control trials (RCTs) to demonstrate their effectiveness, alone or in combination with each other. In addition, HCQ is associated with an increased risk of serious and potentially fatal cardiac arrhythmia (torsades de pointes) secondary to prolongation of the QT interval. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of hydroxychloroquine sulfate supplied from the Strategic National Stockpile to treat adults and adolescents who weigh 50 kg or more and are hospitalized with COVID-19 for whom a clinical trial is not available, or participation is not feasible. Given the above, current guidance is as follows:

- BOP providers should not initiate HCQ or AZ for the purpose of treatment of COVID-19 suspect or confirmed cases in the outpatient setting.
- BOP providers should not initiate HCQ or AZ for pre- or post-exposure prophylaxis in patients with confirmed or suspected exposure to COVID-19
- If a patient was evaluated at the outside hospital and was deemed appropriate to discharge back to the institution the same day, HCQ should not be prescribed, regardless of whether COVID test was confirmed or not.
- If a patient was admitted to the outside hospital and diagnosed with COVID-19, then subsequently discharged, BOP providers may submit non-formulary requests to continue a regimen of HCQ, with or without AZ, that was initiated when the patient was inpatient at the outside hospital
- If a patient was admitted to the outside hospital and diagnosed with COVID-19, then subsequently discharged without having been started on HCQ, HCQ should not be initiated after discharge, even if there is a discharge prescription to initiate.
- The suggested dose and duration of HCQ for adults who weigh ≥ 50 Kg (110 lbs) is 800 mg by mouth on the first day of treatment followed by 400 mg daily for a total treatment duration of four to seven days. Institutions will most likely be receiving patients who have already received at least the initial 800 mg dose and will be completing the course of treatment at a dose of 400 mg / day.
- If a patient is being continued on HCQ, and especially if in combination with AZ, the following precautions should be instituted:
 - Review medications list; discontinue and avoid all other non-critical QT-prolonging agents
 - Obtain a baseline ECG and review QTc. If QTc >500 msec (or >530 msec if QRS >120 msec) consider discontinuing therapy
 - For patients with a history of cardiac disease, arrhythmias, prolonged QTc or are on other QT prolonging medications, on Day 3 of regimen from start of therapy, repeat ECG 2-3 hours

after HCQ dosing. If QTc compared to baseline ECG increases by >30-60 msec or absolute QTc>500 msec (or >530 msec if QRS>120 msec) consider discontinuing therapy.

- ECG monitoring may not be required for patients with a low risk of QTc prolongations (<https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19>)
 - Additional cleaning and disinfecting of the ECG equipment is needed when used on patients who still meet the criteria for isolation due to COVID-19.
- Obtain renal function, hepatic function, serum potassium and magnesium levels; if abnormal, monitor labs during treatment duration or consider discontinuing therapy